Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.
However, the effect of SSc IgGs on smooth muscle cell (SMC) function has not been studied. We determined the effect of SSc IgGs on the muscarinic receptor activation by bethanechol (BeCh; methyl derivate of carbachol) in SMC and smooth muscle strips from rat internal anal sphincter. IgGs were purified from GI-symptomatic SSc patients and normal volunteers, with protein G-Sepharose columns. SMC lengths were determined via computerized digital micrometry. The presence of M3-R and IgG-M3-R complex was determined by Western blot. IgGs from SSc patients but not from normal volunteers caused significant and concentration-dependent inhibition of BeCh response (P Ͻ 0.05). The maximal shortening of 22.2 Ϯ 1.2% caused by 10 Ϫ4 M BeCh was significantly attenuated to 8.3 Ϯ 1.2% by 1 mg/ml of SSc IgGs (P Ͻ 0.05). Experiments performed in smooth muscle strips revealed a similar effect of SSc IgG that was fully reversible. In contrast to the effect on BeCh, the SSc IgGs caused no significant effect (P Ͼ 0.05) on K ϩ depolarization and ␣1-adrenoceptor activation by phenylephrine. Western blot studies revealed the specific presence of SSc IgG-M3-R complex. SSc IgGs attenuated M3-R activation, which was reversible with antibody removal. These data suggest that SSc GI dysmotility may be caused by autoantibodies that inhibit the muscarinic neurotransmission. Future treatment of SSc patients may be directed at the removal or neutralization of these antibodies. systemic sclerosis; rectoanal function; muscarinic receptor; autoantibodies SYSTEMIC SCLEROSIS (scleroderma; SSc) is a systemic connective tissue disease characterized by extensive collagen deposition and sclerosis of the microvasculature and is accompanied by prominent alterations of the autonomic nervous system (14) . As many as 90% of SSc patients have gastrointestinal (GI) symptoms (9, 13) , usually involving the esophagus, and 50 -70% may involve anorectum (21, 44) . Diarrhea, constipation, fecal incontinence, and abdominal distension are commonly present in this patient population (30, 44) .
Gastrointestinal dysmotility in SSc is believed to be neuropathic in etiology, with subsequent smooth muscle atrophy and fibrosis (9) . The exact mechanism of neuropathic dysfunction is still unknown. Numerous autoantibodies have been found in the sera of SSc patients (14, 25) .
A recent study has found a high incidence of antimyenteric neuronal antibodies in the sera of SSc patients with GI symptoms (22) . A follow-up study showed that passive transfer of these antibodies into a rat model significantly disrupts intestinal myoelectric activity (15) , further supporting a neuropathic etiology to dysmotility in SSc patients. Similarly, paraneoplastic syndromes that cause GI dysmotility have also been associated with anti-Hu antibodies that target the myenteric plexus of GI smooth muscle (1, 28) . The precise targeted neuronal antigen in these studies remains to be determined.
Functional autoantibodies in SSc have been identified that specifically inhibit animal colonic smooth muscle (7, 19) . These studies have shown that the SSc IgGs inhibit the smooth muscle contraction caused by carbachol-induced activation of M 3 -R. The data were interpreted to indicate that M 3 -R antibodies from the SSc patients' sera may lead to failure of the cholinergic neurotransmission and, in turn, result in GI motility dysfunction.
Goldblatt et al. (19) showed that serum from patients with SSc inhibited smooth muscle contraction in vitro. In another study, experimentally generated antibodies against the M 3 -R mimicked functional autoantibodies found in Sjogren syndrome (7) .
The purpose of the present study was to characterize autoantibodies present in the serum of SSc patients that may recognize functional components of smooth muscle cell (SMC). Delineation of an antibody-mediated cause of GI dysfunction in SSc would be a major step in understanding the pathogenesis and possible treatment of this progressive and often fatal condition.
The specific aims of the study are 1) to characterize the effect of SSc IgGs on the muscarinic receptor activation in the internal anal sphincter smooth muscle cell, 2) to determine the specificity of this antibody response, and 3) to determine its potential for reversibility.
MATERIALS AND METHODS
Subjects. Seven patients, all female, ages 37 to 83 with initial cutaneous SSc as described by LeRoy et al., were studied. The study was approved by the University's Institutional Review Board. All patients fulfilled the criteria for SSc classification of The American College of Rheumatology. Disease duration varied from 4 to 42 years. All patients had the classic esophageal manometric features of SSc. Two patients had fecal incontinence.
Isolation and purification of IgGs from SSc patients and normal volunteers. Total IgGs were purified from plasma from all SSc patients and from two normal volunteers, by use of recombinant protein G-Sepharose 4B conjugate (Zymed Laboratories, San Fran-cisco, CA) and disposable spin-out columns (G Biosciences, Maryland Heights, MO) as previously described (42) . Briefly, rec-protein G-Sepharose 4B conjugate was diluted 1:10 in 20 mM sodium phosphate pH 7.0, loaded on spin-out columns, and allowed to drain. Then 5 ml of patient plasma diluted 1:2 in saline solution was loaded on the column and washed 10 times with 1 volume of 20 mM sodium phosphate, pH 7.0. Total immunoglobulins (IgGs) were then eluted with 0.1 M acetic acid (pH 2.8) and collected in 2 M Tris, pH 8.0.
Animals and tissue preparation. Male Sprague-Dawley rats (300 -350 g) were euthanized by decapitation and internal anal sphincter (IAS) smooth muscle strips were prepared in oxygenated modified Krebs' physiological solution (KPS) as described before (41) . The composition of KPS was as follows (in mM): 118.07 NaCl, 4.69 KCl, 2.52 CaCl 2, 1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10 glucose.
The experimental protocol of the study was approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University in accordance with the recommendations of the American Association for the Accreditation of Laboratory Animal Care.
Isolation of the SMC and digital micrometry. SMCs from the circular smooth muscle layer of the rat IAS were isolated as described before (27, 41) . Briefly, the IAS smooth muscle tissues prepared above were cut into one or two cubes and incubated in oxygenated KPS containing 0.1% collagenase and 0.01% soybean trypsin inhibitor at 37°C for two successive 1-h periods. After incubation, the mixture was filtered through a 500-m Nitex mesh. The tissue trapped on the mesh was rinsed with 25 ml (5 ϫ 5 ml) of collagenase-free KPS. The tissue was incubated at 37°C, and dispersion of the cells (0 -1 h) was monitored periodically by examining a 10-l aliquot of the mixture under the microscope. The filtrate of the SMC passed through the Nitex mesh was centrifuged at 350 g for 10 min at room temperature. The cells in the pellet were resuspended in oxygenated KPS (at 37°C) at a cell density of 3 ϫ 10 4 cells/ml. SMCs were divided into various aliquots, which were first treated with different concentrations of SSc or normal IgGs (0, 0.3, 0.6, and 1.0 mg/ml) for 10 min. This was followed by the treatment of each of these cell aliquots with bethanechol (BeCh; 10 Ϫ9 to 10 Ϫ3 M) for 5 min. The cells were then fixed with acrolein (final concentration 1%) and transferred onto chrome alum-coated glass slides (Fisher Scientific, Pittsburgh, PA). Individual cell lengths were measured via digital micrometry using phase-contrast microscopy on a custom-assembled microscope (Olympus, Tokyo, Japan), close-circuit video camera (model Pulnix MC-7; PULNIX America, Sunnyvale, CA), and a PC computer. Digital images of cells were stored and cell lengths measured with Image-Pro Plus version 4.0 (Media Cybernetics, Silver Spring, MD).
To establish the selective activation of M3-R by BeCh (10 Ϫ7 to 10 Ϫ4 M), the influence of different concentrations of M3-R selective antagonist darifenacin and nonselective antagonist 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP; 1 ϫ 10 Ϫ9 , 3 ϫ 10
Ϫ9
and 1 ϫ 10 Ϫ8 M) was determined. Measurement of isometric tension. Male Sprague-Dawley rats (300 -350 g) were euthanized by decapitation, and the IAS smooth muscle strips were prepared as described above and transferred to 2-ml muscle baths containing oxygenated KPS at 37°C. Isometric tension was monitored by use of force transducers (model FT03; Grass Instruments, Quincy, MA) and Chart 4.1.2 via PowerLab/8SP data-acquisition system (AD Instruments, Colorado Springs, CO). Each smooth muscle strip was initially stretched to a tension of 0.7 g followed by 90 min of equilibration. Only the smooth muscle strips that developed spontaneous tone were used in this study. The basal tone in each smooth muscle strips was determined at the end of the experiment by the administration of EDTA (50 mM) (2, 11) .
IgG and drug responses. The basal tone in the IAS smooth muscle strips and their responses to BeCh (10 Ϫ9 to 10 Ϫ3 M) were determined before and after 0.1 mg/ml IgGs incubation in the muscle bath for 10 min with 0.1 mg/ml of IgGs from SSc patients or normal volunteers.
To determine the selectivity of the action of SSc IgG on M3-R activation, we compared the effects of K ϩ depolarization by KCl (2.5 to 40 mM) and ␣1-adrenoceptor (␣1-AR) agonist phenylephrine (10 Ϫ9 to 10 Ϫ3 M). M3-receptor identification using Western blot analyses. Dual-color infrared scanning of Western blots was used to determine the presence of M 3-R and its possible association with the IgGs from SSc patients vs. normal individuals. M3-R receptor antibody from Santa Cruz Biotechnology (Santa Cruz, CA) was used for the identification of M 3-R in the rat IAS. The details for the preparation of rat tissue lysates and other details for the Western blots have been described before (37) . Briefly, 30 g of the tissue lysate proteins in 30 l were mixed with 2 ϫ Laemmli sample buffer (with final concentrations 62.5 mM Tris, 1% SDS, 15% glycerol, and 0.005% bromophenol blue, and 2% mercaptoethanol) and placed in a boiling water bath for 5 min and separated by SDS-PAGE (7.5%) as described before (38) . The separated proteins were electrophoretically transferred onto a polyvinylidene difluoride membrane at 100 V for 1 h at 4°C. To block nonspecific antibody binding, the membranes were soaked for 1 h at room temperature in LI-COR blocking buffer (LI-COR Biotechnology, Lincoln, NE). A portion the membrane (containing lanes 2 to 7) was incubated with the IgG purified from the SSc patients whereas the other portion (containing lanes 8 and 9) was incubated with the normal IgGs. These IgGs (SSc or normal; 2 g/ml; diluted in LI-COR buffer containing 0.1% Tween 20) served as the primary antibodies for overnight incubation at 4°C as previously described (35) . M 3-R antibody was added to all the membranes as positive control, as described before (26) . After washing three times with Tris-buffered saline with Tween (TBS-T; 10 min each wash), the membranes were incubated with the IRDye-conjugated secondary antibodies (1:4,000 dilution anti-human IgG-IRDye 680 from Rockland, Gilbertsville, PA and anti-goat IgG-IRDye 800 from LI-COR). The membranes were washed again three times with TBS-T (10 min each wash) and finally kept in PBS buffer for 10 min with constant shaking at room temperature. The membranes were finally scanned with an LI-COR Odyssey Imaging System infrared scanner, and relative densities of M 3-R and human IgG.M3-R complex were determined by line profile analysis via Image-Pro Plus 4.0 (Media Cybernetic).
Drugs and chemicals. BeCh was purchased from Sigma (SigmaAldrich, St. Louis, MO). Darifenacin and 4-DAMP were generous gifts from Pfizer Central Research (Sandwich, Kent, UK) and from Dr. R. B. Barlow (Department of Pharmacology, University of Bristol Medical School, Bristol, UK), respectively.
Statistical analysis. Data are presented as means Ϯ SE of multiple experiments. P values less than 0.05 were considered statistically significant. The concentration-response curves (CRC) were fitted by nonlinear regression using the computer software Prism (GraphPad Software, San Diego, CA). E max (maximum contraction) and pEC50 (negative logarithm of the concentration producing the half-maximum effect) values were calculated from the fitted curves, while pA 2 (negative log concentration of the antagonist producing twofold increase in the EC 50 for BeCh) values were calculated by Schild plot.
RESULTS

Influence of the selective M 3 -R antagonist darifenacin on the effect of BeCh on the IAS SMC.
BeCh caused concentrationdependent decrease in the SMC lengths (Fig. 1) . To determine whether BeCh-induced shortening of the IAS SMC is via M 3 -R activation, we examined the effect of the M 3 -R antagonist darifenacin (3, 23) . Darifenacin IgG obtained from SSc patients caused significant and concentration-dependent attenuation of BeCh-induced CRC in the IAS SMC (*P Ͻ 0.05; n ϭ 5; Fig. 2A ). These data were reproducible in all patients examined. A concentration of 1 mg/ml of SSc IgG attenuated BeCh (1 ϫ 10 Ϫ4 M)-induced shortening of the SMC from 22.7 Ϯ 0.45 to 9.2 Ϯ 0.27% (*P Ͻ 0.05). However, IgGs from normal volunteers (22.4 Ϯ 0.44) had no significant effect (P Ͼ 0.05). The data show an increase in the EC 50 and a decrease in the EC max with BeCh following different concentrations of SSc IgGs, suggesting that noncompetitive inhibition by the SSc IgGs resembles that with the nonselective muscarinic antagonist 4-DAMP (Fig. 2B) . Figure 3A provides typical examples of the changes in lengths of the IAS SMC following different concentrations of normal and SSc IgG and IgGs. Figure 3B shows quantitative data on the actual SMC lengths before and after different concentrations of the IgGs. These data suggest that SSc IgGs attenuate M 3 , respectively. The E max of the IAS SMC in control experiments (with BeCh 1 ϫ 10 Ϫ4 M) was 25.1 Ϯ 2.0% and decreased significantly in a concentration-dependent manner in the presence of 3 ϫ 10 Ϫ9 and 1 ϫ 10 Ϫ8 M 4-DAMP (*P Ͻ 0.05; Fig. 2B ).
Effect of SSc vs. normal IgGs on the SMC contraction by KCl (depolarizing agent) and phenylephrine (␣ 1 -adrenoceptor agonist).
To determine the selectivity of BeCh-mediated M 3 -R inactivation by the SSc IgG on the IAS SMC, we compared the effects of K ϩ depolarization and the ␣ 1 -adrenoceptor (␣ 1 -AR) agonist phenylephrine. Interestingly, in contrast with the attenuation of BeCh-induced effect, neither KCl nor phenylephrineinduced shortening of the IAS SMC was significantly modified either by SSc or normal IgGs (P Ͼ 0.05; Fig. 4 ; n ϭ 4 -6). These data suggest selective attenuation by the SSc IgGs of the muscarinic receptor.
Effect of SSc vs. normal IgGs on M 3 -R activation in the IAS tone.
To determine the effect of the SSc IgGs on M 3 -R activation in the intact smooth muscle, we examined its effect on BeCh-induced increase in the IAS tone. Such experiments were limited to the effects of 0.3 mg/ml SSc IgG because of the limitation of the SSc IgGs available. Data show that in agreement with the effect in the SMC, the IgGs from SSc but not from normal volunteers caused rightward shift in the BeChinduced CRC in the intact smooth muscle strips (*P Ͻ 0.05; n ϭ 3; Fig. 5A ) in a noncompetitive manner. These experiments offer a distinct advantage in determining the reversal effect following the IgG washout. The effect of SSc IgGs was reversible on rigorous washing (from 10 to 12 washes) so that the reversal values were not significantly different from the controls (P Ͼ 0.05; Fig. 5) .
Association of human IgG with the M 3 -R in the SSc IgGs. A dual-color infrared LI-COR Odyssey Imaging System was used to determine an interaction between SSc IgGs and M 3 -R. The blots containing the rat tissue lysates from the IAS were simultaneously incubated with two different primary antibodies as follows: rat M 3 -R (as a positive control from Santa Cruz Biotechnology) and SSc IgGs from SSc patients. Secondary antibodies conjugated with two different fluorophores IRDye 680 (red) against rat (Fig. 6A) and IRDye 800 (green) (Fig. 6B ) against human IgGs were used to determine the presence and binding location of the M 3 -R and the human IgG on the blots. The binding of their respective antibodies at the same position in correspondence with M 3 -R receptor in SSc patients is expected to result in yellow fluorescence as a consequence of merging of red and green fluorescence from the respective secondary antibodies. Such merging was observed only in the case of SSc IgGs and not in the normal IgGs (Fig. 6C) , suggesting an interaction of SSc IgGs with M 3 -R. Prestained Protein Molecular marker (New England Biolabs, Ipswich, MA) was loaded in the first lane to be visualized both by 700 and 800 infrared channels.
DISCUSSION
These data for the first time provide direct evidence that IgGs isolated from SSc patients specifically interfere with the muscarinic receptor activation in SMC and intact smooth muscle of the IAS. These findings have significant implications in the pathophysiology and therapeutic approaches in SSc patients. Data suggest that the IgGs isolated from SSc patients (but not from normal volunteers) attenuate M 3 -R activation by BeCh in freshly isolated SMC of the IAS. Data from the isolated smooth muscle strips are complementary to the SMC data. The concept of M 3 -R inactivation in the IAS SMC by SSc IgGs is supported by the former studies in the murine colonic tissues by Cavill et al. (6) . To implicate the site of SSc IgGs M 3 -R inactivation at the level of SMC, rather than examining the effect directly at SMC, the investigators examined the effect of carbachol in the colonic tissues in the presence of different neurohumoral antagonists.
The significance of M 3 -R at the SMC membrane of the GI tract in the pathophysiology and therapy of the GI disorders is well known (17, 20, 25, 36, 45) . This has been confirmed by using animals with targeted deletion of the M 3 -R gene (16, 46) . Therefore, the effect of M 3 -R attenuation by SSc IgGs in the colonic tissues may explain the underlying pathophysiological mechanisms of the intestinal manifestations of SSc (9, 14) . The effect of SSc IgGs on the anorectum, a region of specific interest in the anorectal motility dysfunction in SSc, however, has not been investigated before.
Studies examining the effect of methacholine (acetyl-␤-methylcholine) (4), another muscarinic agonist, in the human esophagus revealed the preservation of the effect of that agonist, whereas the effect of agents targeting the nerves was severely affected (10) . There are different possibilities for these observations. First is the attenuation by the SSc IgGs of predominantly M 3 -R agonists such as carbachol and bethanechol; methacholine in contrast primarily activates M 1 -R (40) present not only on the SMC but also on the intrinsic nerves. Secondly, differences in the progression of the disease in two groups of patients selected, either in terms of anatomical progress (esophagus vs. large intestine) or in terms of the neuropathic vs. the myopathic stages of the disease, may explain the disparity.
In the present studies, we used BeCh in place of carbachol because of the preferential effect at M 3 -R in the smooth muscles of the GI tract (4, 47) . In the IAS, carbachol produces primarily relaxation of the smooth muscle (24) , perhaps via the activation of nicotinic receptors at the nonadrenergic, noncholinergic inhibitory neurons (4, 5, 8, 12) . Additionally, our data via the use of the selective muscarinic antagonist darifenacin suggest the preferential effect of BeCh at the M 3 -R.
Although it is not possible to completely rule out the nonspecific effects of SSc IgGs on M 3 -R inactivation, the data with K ϩ depolarization and ␣ 1 -AR activation data point toward the selectivity of action. SSc IgGs attenuate the effect of BeCh, but not those of K ϩ depolarization and phenylephrine (␣ 1 -AR agonist). The possibility of patient medication interfering with the M 3 -R activation is unlikely because none of these medications used in these patients is known to interfere with the M 3 -R. In addition, the suppressant effect of SSc IgGs in the IAS smooth muscle was found to be reversible. These observations suggest the possibility of neutralization of deleterious effects of the SSc IgGs following their removal or inactivation in the SSc patients. Whether attenuation of M 3 -R in the IAS SMC by the SSc IgGs is coincidental, is the precursor to the disease, or is a result of the smooth muscle atrophy accompanied with the fibrosis of the smooth muscle is not known.
The present data provide direct support to the hypothesis that autoantibodies targeting GI structures (neuronal and/or smooth muscle) contribute to the clinical manifestations of SSc (14) . The exact mechanism of this M 3 -R inactivation is not known. There is evidence to suggest that these autoantibodies block cholinergic neurotransmission at the G protein-coupled M 3 -R, based on radioligand binding and functional studies in the colon (6, 19) . It has been suggested that the second extracellular loop of M 3 -R may be an epitope for the IgGs as reported in the case of Sjögren's syndrome, another systemic autoimmune disorder (31, 39) . On the basis of these concepts (39) , intravenous infusion of IgG (which works via the neutralization of SSc IgGs) has been used in the symptomatic treatment of SSc (6) .
The observed inhibitory effect of SSc IgGs possibly on M 3 -R in the IAS SMC has wide implications in the GI smooth muscle dysfunction in SSc. Once activated, M 3 -R may initiate the smooth muscle contraction via the influx of Ca 2ϩ and its release from the sarcoplasmic reticulum via inositol 1,4,5-trisphosphate. This activates the Ca 2ϩ /calmodulin/MLCK pathway, leading to the phosphorylation of 20-kDa myosin light chain (p-MLC 20 ). The maintenance of the initiated Fig. 6 . Identification of M3-R in the rat IAS and its association with the human IgGs from SSc patients vs. normal individuals, via the LI-COR Odyssey Imaging System. M3-R in the IAS visualized by use of 700 channel (red) (A) followed by the incubation of the membrane with either the SSc or normal IgGs (which in this case served as the primary antibodies), followed by their identification using anti-human IgG as the secondary antibody, via 800 channel (green) (B). Note the presence of a band corresponding to M3-R (denoted by arrow at 66 kDa) in SSc but not in normal samples. C: merging of A and B suggests significant interaction of SSc but not normal IgGs with M3-R. Lad., ladder D-F: quantification (using line profile analysis) of M3-R, SSc IgG corresponding with M3-R, and interaction of IgGs with M3-R, respectively. All samples were run in duplicate from 3 SSc patients, lanes 2 to 7 and from 1 normal volunteer, lanes 8 and 9. smooth muscle contraction in response to M 3 -R activation, however, may depend largely on the PKC and Rho kinase (RhoA/ROCK) pathways (18, 33, 34, 43) . Both of these pathways converge in inhibiting myosin light chain phosphatase. This prevents the dephosphorylation of p-MLC 20 . It remains to be conclusively determined whether the observed inhibitory effect of the muscarinic receptor activation is primarily at the receptor or it is the result of the downstream signal transduction dysfunction. The association of SSc IgGs with the M 3 -R (Fig. 6) suggests the effect at the receptor, with otherwise intact SMC function.
The relevance of the SSc IgGs-mediated attenuation of the muscarinic receptor in the basal tone and neurotransmission in the IAS is not known at the present time. Initial studies using lower concentrations of the SSc IgGs induced no significant effect on basal IAS tone. A major limitation in such studies is the lack of knowledge of the exact concentrations of the IgGs circulating in the IAS region of SSc patients. Such information may provide appropriate guidelines for selecting the precise concentrations for future studies. Alternatively, despite attenuation of M 3 -R activation, functional antagonism of M 3 -R may be compensated by the redundant mechanisms, as was the case in the targeted deletion of M 3 -R (32).
In conclusion, the studies reveal that IgGs from SSc patients attenuate the muscarinic receptors in the IAS SMC. These data have significant implications in the pathophysiology of rectoanal motility disorders. A definitive relationship between the M 3 -R inactivation with SSc symptomatology may lead to effective therapeutic approaches for the GI dysfunction associated with SSc. Another implication of this study is the potential reversibility of GI scleroderma if autoantibodies can be removed or inactivated.
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